Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

INCR vs BHST: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

INCR Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 10–0 Matrix Metrics)

INCR Overall Winner 6-Pillar Tally: INCR 4 – 2 BHST Matrix Metrics: INCR 10 – 0 BHST

As of Nov 20, 2026, Intercure Ltd. (INCR) is the stronger overall head-to-head candidate over BioHarvest Sciences Inc. (BHST) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). INCR carries a Unified Composite Score of 66.8/100 (BUY) at $3.24 (6.2x Forward P/E, 0.0% operating margin), whereas BHST carries 58.2/100 (HOLD) at $1.30 (N/M Forward P/E, -18.0% operating margin).

  • Technical & Structure Timing Caution: INCR is currently in a Breakdown options structure phase (RSI 32.8); meanwhile BHST is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About INCR vs BHST
INCR NASDAQ Head-to-Head Winner
Intercure Ltd. Ordinary Shares
Pharmaceutical Preparations
$3.24
-7.16% 1D
Market Cap $45.5M
TTM Revenue $243M
Forward P/E 6.2x
Beta / 30D Vol 0.07β · 80% Vol
Unified Composite Score
66.8 / 100 BUY
Tech 68.0 Fund 62.0 Flow 58.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 33
RSI-14: 32.8 · SMA20: $3.86 · SMA50: $4.60
BHST NASDAQ
BioHarvest Sciences Inc. Common Stock
Pharmaceutical Preparations
$1.30
-1.52% 1D
Market Cap $29.9M
TTM Revenue $35M
Forward P/E N/M
Beta / 30D Vol 0.25β · 86% Vol
Unified Composite Score
58.2 / 100 HOLD
Tech 75.0 Fund 57.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.1%), weak momentum, RSI 37
RSI-14: 37.2 · SMA20: $1.55 · SMA50: $1.58

6-Pillar Scorecard Institutional Category Breakdown (INCR 4 – 2 BHST)

Columns: Metric · INCR · BHST
1. Valuation Multiples INCR
Forward P/E 6.2x N/M
Trailing P/E 6.2x N/M
PEG Ratio N/M N/M
EV / Revenue 0.2x 0.7x
2. Growth & Scale INCR
Revenue Growth (YoY) +23.9% +3.8%
Earnings Growth (YoY) -84.7% +0.0%
TTM Revenue (USD) $243M $35M
Market Cap $45.5M $29.9M
3. Profitability & Quality INCR
Gross Margin 16.7% 59.0%
Operating Margin 0.0% -18.0%
Net Profit Margin -13.2% -31.2%
Return on Equity (ROE) -9.3% -142.5%
4. Balance Sheet & Cash Flow BHST
Cash Generation (TTM) -$55M EBITDA -$9.4M
Cash Flow Margin -22.8% EBITDA Mgn -26.6%
Net Cash / Leverage $7.59 Book/Sh · -9.3% ROE $5.1M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning INCR
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 72.9% (<1st %ile) N/A (N/A)
Put/Call OI Skew 3.00x (Put-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat BHST
OpEx & R&D Intensity 16.7% of Rev ($41M) 77.0% of Rev ($27M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Packaged Foods Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: INCR (10) vs BHST (0)
Institutional Metric INCR BHST Criterion Row Edge
Market Capitalization
Scale
$45.5M $29.9M Larger Scale INCR
Trailing P/E Ratio
Valuation
6.2x N/M Lower Multiple INCR
Forward P/E Ratio
Valuation
6.2x N/M Lower Multiple INCR
Revenue Growth (YoY)
Growth
+23.9% +3.8% Higher Growth INCR
Operating Margin (TTM)
Profitability
0.0% -18.0% Higher Margin INCR
Net Profit Margin
Profitability
-13.2% -31.2% Higher Margin INCR
Return on Equity (ROE)
Capital Efficiency
-9.3% -142.5% Higher ROE INCR
52-Week Range Position
Momentum
47% ($1–$6) 6% ($1–$7) Stronger Trend INCR
Beta / 30D Volatility
Risk Regime
0.07β · 80% Vol 0.25β · 86% Vol Lower Realized Risk INCR
Unified Institutional Score
Composite Signal
66.8 / 100 (BUY) 58.2 / 100 (HOLD) Higher Composite INCR
Trailing 12M Revenue (USD)
Operating Scale
$243M $35M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
16.7% 59.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.2x EV/Rev N/M PEG · 0.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$55M EBITDA ($7.59 Book/Sh · -9.3% ROE) -$9.4M ($5.1M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BHST +4.24 pp
INCR: -26.86% · BHST: -22.62%
3M Horizon INCR +309.11 pp
INCR: +272.84% · BHST: -36.27%
6M Horizon INCR +344.0 pp
INCR: +278.95% · BHST: -65.05%
1Y Horizon INCR +221.19 pp
INCR: +141.79% · BHST: -79.4%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on INCR vs BHST. Trailing 12-month operating profitability (INCR 0.0% vs BHST -18.0%) and valuation multiples (INCR 6.2x vs BHST N/M Forward P/E) are benchmarked directly in Pillar 4 below.

INCR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$243M
Gross Margin16.7%
Op. Margin0.0%
ROE / Fwd P/E-9.3% · 6.2x
BHST ADR TTM Benchmark FX-Normalized USD
TTM Revenue$35M
Gross Margin59.0%
Op. Margin-18.0%
ROE / Fwd P/E-142.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
INCR BREAKDOWN
59d in phase · OBV ACCUMULATION
Current IV 72.9%
IV Percentile <1st %ile
Put/Call OI Skew 3.00x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact INCR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BHST UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BHST Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
INCR Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $45.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment 16.7% of Rev ($41M)
90D Engineering Disclosures 0 Published
BHST Moat Profile Cyclical / Execution-Driven Positioning
Packaged Foods Operator
Competes within the Packaged Foods value chain with $29.9M market capitalization and -18.0% operating margin.
OpEx & R&D Reinvestment 77.0% of Rev ($27M)
90D Engineering Disclosures 0 Published

Investor FAQ INCR vs BHST Key Questions & Quantitative Answers

As of Nov 20, 2026, Intercure Ltd. (INCR) is the stronger overall head-to-head candidate over BioHarvest Sciences Inc. (BHST) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). INCR carries a Unified Composite Score of 66.8/100 (BUY) at $3.24 (6.2x Forward P/E, 0.0% operating margin), whereas BHST carries 58.2/100 (HOLD) at $1.30 (N/M Forward P/E, -18.0% operating margin). Technical & Structure Timing Caution: INCR is currently in a Breakdown options structure phase (RSI 32.8); meanwhile BHST is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

INCR leads the Growth & Scale pillar: INCR posts +23.9% YoY revenue growth and -84.7% YoY earnings growth on $243M TTM revenue (16.7% gross margin, 0.0% operating margin), compared with BHST at +3.8% YoY revenue growth and +0.0% YoY earnings growth on $35M TTM revenue (59.0% gross margin, -18.0% operating margin). On trailing 12-month operating scale, INCR generates $243M in USD-normalized revenue versus $35M for BHST. In operating R&D and SG&A reinvestment, INCR deploys 16.7% of Rev ($41M) (0 90-day corporate R&D disclosures) versus 77.0% of Rev ($27M) (0 disclosures) for BHST.

INCR screens cheaper on headline valuation multiples. INCR trades at 6.2x Forward P/E, 6.2x Trailing P/E, N/M PEG, and 0.2x EV/Revenue (-22.8% EBITDA margin), whereas BHST trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.7x EV/Revenue (-26.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against INCR (-9.3% ROE) versus BHST (-142.5% ROE) capital efficiency.

In options market volatility and institutional positioning, INCR carries 72.9% implied volatility (<1st %ile, Compressed (<25th %ile)), a 3.00x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (0.07β · 80% Vol realized risk). By comparison, BHST carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.25β · 86% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.